Article Text
Statistics from Altmetric.com
Q In patients with stable coronary artery disease (CAD) and preserved left ventricular (LV) function, is trandolapril better than placebo for reducing the risk of cardiovascular (CV) death or other CV events?
Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★☆☆ Internal medicine ★★★★★☆☆ Cardiology ★★★★★★☆
METHODS
Design:
randomised placebo controlled trial (Prevention of Events with Angiotensin Converting Enzyme Inhibition [PEACE] trial).
Allocation:
concealed.*
Blinding:
blinded (clinicians, patients, {data collectors, and outcome assessors}†).*
Follow up period:
median 4.8 years.
Setting:
187 centres in the US, Canada, and Italy.
Patients:
8290 patients (mean age 64 y, 82% men) who had documented CAD (⩾1 of myocardial infarction [MI], coronary artery bypass grafting [CABG] or percutaneous coronary intervention [PCI] ⩾3 months before enrolment; or obstruction of ⩾50% of the luminal diameter of ⩾1 native vessel or coronary angiography); LV ejection fraction >40% on ventriculography or echocardiograpy, a qualitatively normal left ventriculogram, or the absence of LV wall motion abnormalities on echocardiography; …